Organogenesis Holdings Inc.
Organogenesis Holdings Inc. (ORGO) Stock Competitors & Peer Comparison
See (ORGO) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ORGO | $4.89 | +9.40% | 620.3M | -34.93 | -$0.14 | N/A |
| ZTS | $156.62 | +0.65% | 69.4B | 26.90 | $5.82 | +1.23% |
| TAK | $15.52 | +1.37% | 49B | 53.50 | $0.29 | +3.89% |
| HLN | $9.82 | +0.10% | 44.6B | 21.78 | $0.45 | +1.79% |
| TEVA | $18.46 | -1.81% | 21.2B | -123.13 | -$0.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $135.43 | +0.11% | 13.4B | 40.07 | $3.38 | N/A |
| VTRS | $10.65 | -0.37% | 12.4B | -3.63 | -$2.93 | +4.47% |
| RDY | $14.51 | +0.62% | 12.1B | 18.61 | $0.78 | +0.63% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
Stock Comparison
ORGO vs ZTS Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ZTS has a market cap of 69.4B. Regarding current trading prices, ORGO is priced at $4.89, while ZTS trades at $156.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ZTS's P/E ratio is 26.90. In terms of profitability, ORGO's ROE is -0.03%, compared to ZTS's ROE of +0.53%. Regarding short-term risk, ORGO is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check ZTS's competition here
ORGO vs TAK Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, TAK has a market cap of 49B. Regarding current trading prices, ORGO is priced at $4.89, while TAK trades at $15.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas TAK's P/E ratio is 53.50. In terms of profitability, ORGO's ROE is -0.03%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ORGO is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check TAK's competition here
ORGO vs HLN Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, HLN has a market cap of 44.6B. Regarding current trading prices, ORGO is priced at $4.89, while HLN trades at $9.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas HLN's P/E ratio is 21.78. In terms of profitability, ORGO's ROE is -0.03%, compared to HLN's ROE of +0.09%. Regarding short-term risk, ORGO is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check HLN's competition here
ORGO vs TEVA Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, TEVA has a market cap of 21.2B. Regarding current trading prices, ORGO is priced at $4.89, while TEVA trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas TEVA's P/E ratio is -123.13. In terms of profitability, ORGO's ROE is -0.03%, compared to TEVA's ROE of -0.03%. Regarding short-term risk, ORGO is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check TEVA's competition here
ORGO vs ITCI Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ORGO is priced at $4.89, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ORGO's ROE is -0.03%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, ORGO is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check ITCI's competition here
ORGO vs NBIX Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, NBIX has a market cap of 13.4B. Regarding current trading prices, ORGO is priced at $4.89, while NBIX trades at $135.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas NBIX's P/E ratio is 40.07. In terms of profitability, ORGO's ROE is -0.03%, compared to NBIX's ROE of +0.13%. Regarding short-term risk, ORGO is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check NBIX's competition here
ORGO vs VTRS Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, VTRS has a market cap of 12.4B. Regarding current trading prices, ORGO is priced at $4.89, while VTRS trades at $10.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas VTRS's P/E ratio is -3.63. In terms of profitability, ORGO's ROE is -0.03%, compared to VTRS's ROE of -0.20%. Regarding short-term risk, ORGO is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check VTRS's competition here
ORGO vs RDY Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, RDY has a market cap of 12.1B. Regarding current trading prices, ORGO is priced at $4.89, while RDY trades at $14.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas RDY's P/E ratio is 18.61. In terms of profitability, ORGO's ROE is -0.03%, compared to RDY's ROE of +0.17%. Regarding short-term risk, ORGO is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check RDY's competition here
ORGO vs CTLT Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ORGO is priced at $4.89, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ORGO's ROE is -0.03%, compared to CTLT's ROE of -0.06%. Regarding short-term risk, ORGO is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check CTLT's competition here
ORGO vs ELAN Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ELAN has a market cap of 8.9B. Regarding current trading prices, ORGO is priced at $4.89, while ELAN trades at $17.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ELAN's P/E ratio is 20.35. In terms of profitability, ORGO's ROE is -0.03%, compared to ELAN's ROE of +0.07%. Regarding short-term risk, ORGO is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check ELAN's competition here
ORGO vs RGC Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, RGC has a market cap of 6.3B. Regarding current trading prices, ORGO is priced at $4.89, while RGC trades at $12.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas RGC's P/E ratio is -1280.00. In terms of profitability, ORGO's ROE is -0.03%, compared to RGC's ROE of -0.50%. Regarding short-term risk, ORGO is more volatile compared to RGC. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check RGC's competition here
ORGO vs LNTH Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, LNTH has a market cap of 4B. Regarding current trading prices, ORGO is priced at $4.89, while LNTH trades at $58.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas LNTH's P/E ratio is 15.48. In terms of profitability, ORGO's ROE is -0.03%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, ORGO is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check LNTH's competition here
ORGO vs PRGO Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, PRGO has a market cap of 3.4B. Regarding current trading prices, ORGO is priced at $4.89, while PRGO trades at $24.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas PRGO's P/E ratio is -56.94. In terms of profitability, ORGO's ROE is -0.03%, compared to PRGO's ROE of -0.02%. Regarding short-term risk, ORGO is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check PRGO's competition here
ORGO vs INDV Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, INDV has a market cap of 3B. Regarding current trading prices, ORGO is priced at $4.89, while INDV trades at $24.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas INDV's P/E ratio is 30.02. In terms of profitability, ORGO's ROE is -0.03%, compared to INDV's ROE of -0.48%. Regarding short-term risk, ORGO is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check INDV's competition here
ORGO vs AMRX Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, AMRX has a market cap of 3B. Regarding current trading prices, ORGO is priced at $4.89, while AMRX trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas AMRX's P/E ratio is 959.00. In terms of profitability, ORGO's ROE is -0.03%, compared to AMRX's ROE of -0.03%. Regarding short-term risk, ORGO is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check AMRX's competition here
ORGO vs HCM Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, HCM has a market cap of 2.8B. Regarding current trading prices, ORGO is priced at $4.89, while HCM trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas HCM's P/E ratio is 6.08. In terms of profitability, ORGO's ROE is -0.03%, compared to HCM's ROE of +0.05%. Regarding short-term risk, ORGO is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check HCM's competition here
ORGO vs BHC Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, BHC has a market cap of 2.8B. Regarding current trading prices, ORGO is priced at $4.89, while BHC trades at $7.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas BHC's P/E ratio is 28.81. In terms of profitability, ORGO's ROE is -0.03%, compared to BHC's ROE of -0.09%. Regarding short-term risk, ORGO is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check BHC's competition here
ORGO vs ALVO Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ALVO has a market cap of 2.6B. Regarding current trading prices, ORGO is priced at $4.89, while ALVO trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ALVO's P/E ratio is 36.74. In terms of profitability, ORGO's ROE is -0.03%, compared to ALVO's ROE of -0.21%. Regarding short-term risk, ORGO is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check ALVO's competition here
ORGO vs SUPN Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, ORGO is priced at $4.89, while SUPN trades at $44.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas SUPN's P/E ratio is 39.03. In terms of profitability, ORGO's ROE is -0.03%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, ORGO is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check SUPN's competition here
ORGO vs ALVOW Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ALVOW has a market cap of 2.5B. Regarding current trading prices, ORGO is priced at $4.89, while ALVOW trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ALVOW's P/E ratio is N/A. In terms of profitability, ORGO's ROE is -0.03%, compared to ALVOW's ROE of -0.21%. Regarding short-term risk, ORGO is more volatile compared to ALVOW. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check ALVOW's competition here
ORGO vs DCPH Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ORGO is priced at $4.89, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ORGO's ROE is -0.03%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ORGO is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check DCPH's competition here
ORGO vs ANIP Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ANIP has a market cap of 2B. Regarding current trading prices, ORGO is priced at $4.89, while ANIP trades at $91.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ANIP's P/E ratio is -131.90. In terms of profitability, ORGO's ROE is -0.03%, compared to ANIP's ROE of -0.03%. Regarding short-term risk, ORGO is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check ANIP's competition here
ORGO vs EMBCV Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ORGO is priced at $4.89, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ORGO's ROE is -0.03%, compared to EMBCV's ROE of +0.71%. Regarding short-term risk, ORGO is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for ORGO.Check EMBCV's competition here
ORGO vs TARO Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ORGO is priced at $4.89, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas TARO's P/E ratio is 30.05. In terms of profitability, ORGO's ROE is -0.03%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ORGO is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check TARO's competition here
ORGO vs BGM Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, BGM has a market cap of 1.5B. Regarding current trading prices, ORGO is priced at $4.89, while BGM trades at $8.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas BGM's P/E ratio is -26.41. In terms of profitability, ORGO's ROE is -0.03%, compared to BGM's ROE of -0.03%. Regarding short-term risk, ORGO is more volatile compared to BGM. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check BGM's competition here
ORGO vs AVDL Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, AVDL has a market cap of 1.5B. Regarding current trading prices, ORGO is priced at $4.89, while AVDL trades at $15.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas AVDL's P/E ratio is -762.00. In terms of profitability, ORGO's ROE is -0.03%, compared to AVDL's ROE of -0.04%. Regarding short-term risk, ORGO is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check AVDL's competition here
ORGO vs HROW Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, ORGO is priced at $4.89, while HROW trades at $39.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas HROW's P/E ratio is -139.71. In terms of profitability, ORGO's ROE is -0.03%, compared to HROW's ROE of -0.18%. Regarding short-term risk, ORGO is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check HROW's competition here
ORGO vs AMPH Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, AMPH has a market cap of 1.4B. Regarding current trading prices, ORGO is priced at $4.89, while AMPH trades at $30.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas AMPH's P/E ratio is 11.42. In terms of profitability, ORGO's ROE is -0.03%, compared to AMPH's ROE of +0.18%. Regarding short-term risk, ORGO is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check AMPH's competition here
ORGO vs PAHC Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, ORGO is priced at $4.89, while PAHC trades at $32.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas PAHC's P/E ratio is 41.62. In terms of profitability, ORGO's ROE is -0.03%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, ORGO is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check PAHC's competition here
ORGO vs EVO Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, EVO has a market cap of 1.3B. Regarding current trading prices, ORGO is priced at $4.89, while EVO trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas EVO's P/E ratio is -7.14. In terms of profitability, ORGO's ROE is -0.03%, compared to EVO's ROE of -0.17%. Regarding short-term risk, ORGO is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check EVO's competition here
ORGO vs TLRY Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, TLRY has a market cap of 1.3B. Regarding current trading prices, ORGO is priced at $4.89, while TLRY trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas TLRY's P/E ratio is -0.47. In terms of profitability, ORGO's ROE is -0.03%, compared to TLRY's ROE of -0.78%. Regarding short-term risk, ORGO is more volatile compared to TLRY. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check TLRY's competition here
ORGO vs COLL Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, COLL has a market cap of 1.2B. Regarding current trading prices, ORGO is priced at $4.89, while COLL trades at $39.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas COLL's P/E ratio is 36.90. In terms of profitability, ORGO's ROE is -0.03%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ORGO is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check COLL's competition here
ORGO vs DVAX Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, DVAX has a market cap of 1.2B. Regarding current trading prices, ORGO is priced at $4.89, while DVAX trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas DVAX's P/E ratio is -23.33. In terms of profitability, ORGO's ROE is -0.03%, compared to DVAX's ROE of -0.09%. Regarding short-term risk, ORGO is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check DVAX's competition here
ORGO vs PCRX Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, PCRX has a market cap of 1.2B. Regarding current trading prices, ORGO is priced at $4.89, while PCRX trades at $25.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas PCRX's P/E ratio is -9.40. In terms of profitability, ORGO's ROE is -0.03%, compared to PCRX's ROE of -0.17%. Regarding short-term risk, ORGO is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check PCRX's competition here
ORGO vs CRON Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, CRON has a market cap of 995.6M. Regarding current trading prices, ORGO is priced at $4.89, while CRON trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas CRON's P/E ratio is 52.00. In terms of profitability, ORGO's ROE is -0.03%, compared to CRON's ROE of +0.02%. Regarding short-term risk, ORGO is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check CRON's competition here
ORGO vs PETQ Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ORGO is priced at $4.89, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ORGO's ROE is -0.03%, compared to PETQ's ROE of +0.12%. Regarding short-term risk, ORGO is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check PETQ's competition here
ORGO vs EMBC Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, EMBC has a market cap of 841M. Regarding current trading prices, ORGO is priced at $4.89, while EMBC trades at $14.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas EMBC's P/E ratio is 10.13. In terms of profitability, ORGO's ROE is -0.03%, compared to EMBC's ROE of -0.11%. Regarding short-term risk, ORGO is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check EMBC's competition here
ORGO vs SIGA Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, SIGA has a market cap of 653.8M. Regarding current trading prices, ORGO is priced at $4.89, while SIGA trades at $9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas SIGA's P/E ratio is 8.01. In terms of profitability, ORGO's ROE is -0.03%, compared to SIGA's ROE of +0.41%. Regarding short-term risk, ORGO is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check SIGA's competition here
ORGO vs SNDL Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, SNDL has a market cap of 579.1M. Regarding current trading prices, ORGO is priced at $4.89, while SNDL trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas SNDL's P/E ratio is -8.33. In terms of profitability, ORGO's ROE is -0.03%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, ORGO is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check SNDL's competition here
ORGO vs BDSI Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ORGO is priced at $4.89, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ORGO's ROE is -0.03%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ORGO is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check BDSI's competition here
ORGO vs EOLS Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, EOLS has a market cap of 496.8M. Regarding current trading prices, ORGO is priced at $4.89, while EOLS trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas EOLS's P/E ratio is -7.92. In terms of profitability, ORGO's ROE is -0.03%, compared to EOLS's ROE of +17.91%. Regarding short-term risk, ORGO is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check EOLS's competition here
ORGO vs EBS Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, EBS has a market cap of 493.2M. Regarding current trading prices, ORGO is priced at $4.89, while EBS trades at $9.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas EBS's P/E ratio is 3.53. In terms of profitability, ORGO's ROE is -0.03%, compared to EBS's ROE of +0.27%. Regarding short-term risk, ORGO is more volatile compared to EBS. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check EBS's competition here
ORGO vs ESPR Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ESPR has a market cap of 437.4M. Regarding current trading prices, ORGO is priced at $4.89, while ESPR trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ESPR's P/E ratio is -4.02. In terms of profitability, ORGO's ROE is -0.03%, compared to ESPR's ROE of +0.32%. Regarding short-term risk, ORGO is more volatile compared to ESPR. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check ESPR's competition here
ORGO vs KMDA Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, KMDA has a market cap of 412.9M. Regarding current trading prices, ORGO is priced at $4.89, while KMDA trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas KMDA's P/E ratio is 22.44. In terms of profitability, ORGO's ROE is -0.03%, compared to KMDA's ROE of +0.07%. Regarding short-term risk, ORGO is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check KMDA's competition here
ORGO vs AQST Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, AQST has a market cap of 396.9M. Regarding current trading prices, ORGO is priced at $4.89, while AQST trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas AQST's P/E ratio is -5.77. In terms of profitability, ORGO's ROE is -0.03%, compared to AQST's ROE of +1.09%. Regarding short-term risk, ORGO is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check AQST's competition here
ORGO vs ZYBT Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ZYBT has a market cap of 330.8M. Regarding current trading prices, ORGO is priced at $4.89, while ZYBT trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ZYBT's P/E ratio is 232.67. In terms of profitability, ORGO's ROE is -0.03%, compared to ZYBT's ROE of +0.04%. Regarding short-term risk, ORGO is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for ORGO.Check ZYBT's competition here
ORGO vs CGC Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, CGC has a market cap of 304.5M. Regarding current trading prices, ORGO is priced at $4.89, while CGC trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas CGC's P/E ratio is -0.42. In terms of profitability, ORGO's ROE is -0.03%, compared to CGC's ROE of -0.99%. Regarding short-term risk, ORGO is more volatile compared to CGC. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check CGC's competition here
ORGO vs ALIM Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ORGO is priced at $4.89, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ORGO's ROE is -0.03%, compared to ALIM's ROE of -0.24%. Regarding short-term risk, ORGO is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check ALIM's competition here
ORGO vs LFCR Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, LFCR has a market cap of 284.3M. Regarding current trading prices, ORGO is priced at $4.89, while LFCR trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas LFCR's P/E ratio is -5.98. In terms of profitability, ORGO's ROE is -0.03%, compared to LFCR's ROE of -2.53%. Regarding short-term risk, ORGO is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check LFCR's competition here
ORGO vs ACB Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ACB has a market cap of 280.7M. Regarding current trading prices, ORGO is priced at $4.89, while ACB trades at $4.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ACB's P/E ratio is -124.75. In terms of profitability, ORGO's ROE is -0.03%, compared to ACB's ROE of +0.00%. Regarding short-term risk, ORGO is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check ACB's competition here
ORGO vs LNDC Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ORGO is priced at $4.89, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ORGO's ROE is -0.03%, compared to LNDC's ROE of -10.27%. Regarding short-term risk, ORGO is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check LNDC's competition here
ORGO vs TKNO Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, TKNO has a market cap of 254.2M. Regarding current trading prices, ORGO is priced at $4.89, while TKNO trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas TKNO's P/E ratio is -12.18. In terms of profitability, ORGO's ROE is -0.03%, compared to TKNO's ROE of -0.27%. Regarding short-term risk, ORGO is more volatile compared to TKNO. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check TKNO's competition here
ORGO vs TYHT Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ORGO is priced at $4.89, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ORGO's ROE is -0.03%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ORGO is more volatile compared to TYHT. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check TYHT's competition here
ORGO vs OGI Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, OGI has a market cap of 214.2M. Regarding current trading prices, ORGO is priced at $4.89, while OGI trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas OGI's P/E ratio is 160.00. In terms of profitability, ORGO's ROE is -0.03%, compared to OGI's ROE of +0.02%. Regarding short-term risk, ORGO is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for ORGO.Check OGI's competition here
ORGO vs IRWD Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, IRWD has a market cap of 206.3M. Regarding current trading prices, ORGO is priced at $4.89, while IRWD trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas IRWD's P/E ratio is -25.40. In terms of profitability, ORGO's ROE is -0.03%, compared to IRWD's ROE of +0.03%. Regarding short-term risk, ORGO is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for ORGO.Check IRWD's competition here
ORGO vs SXTC Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, SXTC has a market cap of 182.2M. Regarding current trading prices, ORGO is priced at $4.89, while SXTC trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas SXTC's P/E ratio is -0.68. In terms of profitability, ORGO's ROE is -0.03%, compared to SXTC's ROE of +0.17%. Regarding short-term risk, ORGO is more volatile compared to SXTC. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check SXTC's competition here
ORGO vs DERM Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, DERM has a market cap of 182.1M. Regarding current trading prices, ORGO is priced at $4.89, while DERM trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas DERM's P/E ratio is -20.19. In terms of profitability, ORGO's ROE is -0.03%, compared to DERM's ROE of -0.49%. Regarding short-term risk, ORGO is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check DERM's competition here
ORGO vs REPH Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ORGO is priced at $4.89, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas REPH's P/E ratio is -8.04. In terms of profitability, ORGO's ROE is -0.03%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ORGO is more volatile compared to REPH. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check REPH's competition here
ORGO vs BIOA Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, BIOA has a market cap of 165.3M. Regarding current trading prices, ORGO is priced at $4.89, while BIOA trades at $4.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas BIOA's P/E ratio is -0.68. In terms of profitability, ORGO's ROE is -0.03%, compared to BIOA's ROE of -0.25%. Regarding short-term risk, ORGO is more volatile compared to BIOA. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check BIOA's competition here
ORGO vs THTX Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, THTX has a market cap of 149.9M. Regarding current trading prices, ORGO is priced at $4.89, while THTX trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas THTX's P/E ratio is -17.16. In terms of profitability, ORGO's ROE is -0.03%, compared to THTX's ROE of +0.38%. Regarding short-term risk, ORGO is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check THTX's competition here
ORGO vs SCTL Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ORGO is priced at $4.89, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ORGO's ROE is -0.03%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ORGO is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check SCTL's competition here
ORGO vs PROC Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, PROC has a market cap of 114M. Regarding current trading prices, ORGO is priced at $4.89, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas PROC's P/E ratio is 1.53. In terms of profitability, ORGO's ROE is -0.03%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ORGO is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check PROC's competition here
ORGO vs OPTN Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ORGO is priced at $4.89, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ORGO's ROE is -0.03%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, ORGO is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check OPTN's competition here
ORGO vs CRDL Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, CRDL has a market cap of 96.7M. Regarding current trading prices, ORGO is priced at $4.89, while CRDL trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas CRDL's P/E ratio is -3.34. In terms of profitability, ORGO's ROE is -0.03%, compared to CRDL's ROE of -2.10%. Regarding short-term risk, ORGO is more volatile compared to CRDL. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check CRDL's competition here
ORGO vs ZOM Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ORGO is priced at $4.89, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ORGO's ROE is -0.03%, compared to ZOM's ROE of -0.52%. Regarding short-term risk, ORGO is more volatile compared to ZOM. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check ZOM's competition here
ORGO vs INCR Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, INCR has a market cap of 91.6M. Regarding current trading prices, ORGO is priced at $4.89, while INCR trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas INCR's P/E ratio is -3.82. In terms of profitability, ORGO's ROE is -0.03%, compared to INCR's ROE of -0.15%. Regarding short-term risk, ORGO is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check INCR's competition here
ORGO vs GRVI Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ORGO is priced at $4.89, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ORGO's ROE is -0.03%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, ORGO is more volatile compared to GRVI. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check GRVI's competition here
ORGO vs ASRT Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ASRT has a market cap of 75.6M. Regarding current trading prices, ORGO is priced at $4.89, while ASRT trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ASRT's P/E ratio is -1.75. In terms of profitability, ORGO's ROE is -0.03%, compared to ASRT's ROE of -0.38%. Regarding short-term risk, ORGO is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check ASRT's competition here
ORGO vs ZYNE Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ORGO is priced at $4.89, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ORGO's ROE is -0.03%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ORGO is more volatile compared to ZYNE. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check ZYNE's competition here
ORGO vs QNTM Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, QNTM has a market cap of 68.9M. Regarding current trading prices, ORGO is priced at $4.89, while QNTM trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas QNTM's P/E ratio is -1.59. In terms of profitability, ORGO's ROE is -0.03%, compared to QNTM's ROE of -2.90%. Regarding short-term risk, ORGO is more volatile compared to QNTM. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check QNTM's competition here
ORGO vs SSIC Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ORGO is priced at $4.89, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ORGO's ROE is -0.03%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, ORGO is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check SSIC's competition here
ORGO vs KALA Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, KALA has a market cap of 64.7M. Regarding current trading prices, ORGO is priced at $4.89, while KALA trades at $9.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas KALA's P/E ratio is -1.55. In terms of profitability, ORGO's ROE is -0.03%, compared to KALA's ROE of -6.86%. Regarding short-term risk, ORGO is more volatile compared to KALA. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check KALA's competition here
ORGO vs VLNS Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ORGO is priced at $4.89, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ORGO's ROE is -0.03%, compared to VLNS's ROE of N/A. Regarding short-term risk, ORGO is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check VLNS's competition here
ORGO vs DRRX Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, DRRX has a market cap of 59.6M. Regarding current trading prices, ORGO is priced at $4.89, while DRRX trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas DRRX's P/E ratio is -4.47. In terms of profitability, ORGO's ROE is -0.03%, compared to DRRX's ROE of -0.71%. Regarding short-term risk, ORGO is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check DRRX's competition here
ORGO vs JUPW Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ORGO is priced at $4.89, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ORGO's ROE is -0.03%, compared to JUPW's ROE of -0.32%. Regarding short-term risk, ORGO is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for ORGO.Check JUPW's competition here
ORGO vs CPIX Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, CPIX has a market cap of 49.2M. Regarding current trading prices, ORGO is priced at $4.89, while CPIX trades at $3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas CPIX's P/E ratio is -14.95. In terms of profitability, ORGO's ROE is -0.03%, compared to CPIX's ROE of -0.11%. Regarding short-term risk, ORGO is more volatile compared to CPIX. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check CPIX's competition here
ORGO vs EGRX Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, EGRX has a market cap of 41.4M. Regarding current trading prices, ORGO is priced at $4.89, while EGRX trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas EGRX's P/E ratio is 3.75. In terms of profitability, ORGO's ROE is -0.03%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, ORGO is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check EGRX's competition here
ORGO vs RMTI Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, RMTI has a market cap of 39.3M. Regarding current trading prices, ORGO is priced at $4.89, while RMTI trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas RMTI's P/E ratio is -16.29. In terms of profitability, ORGO's ROE is -0.03%, compared to RMTI's ROE of -0.07%. Regarding short-term risk, ORGO is more volatile compared to RMTI. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check RMTI's competition here
ORGO vs QLI Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ORGO is priced at $4.89, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas QLI's P/E ratio is -4.92. In terms of profitability, ORGO's ROE is -0.03%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ORGO is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check QLI's competition here
ORGO vs SCYX Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, SCYX has a market cap of 34.2M. Regarding current trading prices, ORGO is priced at $4.89, while SCYX trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas SCYX's P/E ratio is -2.04. In terms of profitability, ORGO's ROE is -0.03%, compared to SCYX's ROE of -0.37%. Regarding short-term risk, ORGO is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check SCYX's competition here
ORGO vs HEXO Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ORGO is priced at $4.89, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ORGO's ROE is -0.03%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ORGO is more volatile compared to HEXO. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check HEXO's competition here
ORGO vs COSM Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, COSM has a market cap of 25.1M. Regarding current trading prices, ORGO is priced at $4.89, while COSM trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas COSM's P/E ratio is -0.81. In terms of profitability, ORGO's ROE is -0.03%, compared to COSM's ROE of -0.55%. Regarding short-term risk, ORGO is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for ORGO.Check COSM's competition here
ORGO vs CYTH Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ORGO is priced at $4.89, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ORGO's ROE is -0.03%, compared to CYTH's ROE of +3.20%. Regarding short-term risk, ORGO is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check CYTH's competition here
ORGO vs IXHL Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, IXHL has a market cap of 17.3M. Regarding current trading prices, ORGO is priced at $4.89, while IXHL trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas IXHL's P/E ratio is -0.48. In terms of profitability, ORGO's ROE is -0.03%, compared to IXHL's ROE of -3.57%. Regarding short-term risk, ORGO is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for ORGO.Check IXHL's competition here
ORGO vs ACRX Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ORGO is priced at $4.89, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ORGO's ROE is -0.03%, compared to ACRX's ROE of -1.51%. Regarding short-term risk, ORGO is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for ORGO.Check ACRX's competition here
ORGO vs PRPH Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, PRPH has a market cap of 13.7M. Regarding current trading prices, ORGO is priced at $4.89, while PRPH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas PRPH's P/E ratio is -0.16. In terms of profitability, ORGO's ROE is -0.03%, compared to PRPH's ROE of -2.30%. Regarding short-term risk, ORGO is more volatile compared to PRPH. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check PRPH's competition here
ORGO vs AYTU Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, AYTU has a market cap of 13.6M. Regarding current trading prices, ORGO is priced at $4.89, while AYTU trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas AYTU's P/E ratio is -1.48. In terms of profitability, ORGO's ROE is -0.03%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, ORGO is more volatile compared to AYTU. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check AYTU's competition here
ORGO vs GELS Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, GELS has a market cap of 12.9M. Regarding current trading prices, ORGO is priced at $4.89, while GELS trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas GELS's P/E ratio is -3.69. In terms of profitability, ORGO's ROE is -0.03%, compared to GELS's ROE of -0.07%. Regarding short-term risk, ORGO is more volatile compared to GELS. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check GELS's competition here
ORGO vs TXMD Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, TXMD has a market cap of 12.7M. Regarding current trading prices, ORGO is priced at $4.89, while TXMD trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas TXMD's P/E ratio is -22.00. In terms of profitability, ORGO's ROE is -0.03%, compared to TXMD's ROE of -0.02%. Regarding short-term risk, ORGO is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check TXMD's competition here
ORGO vs FLGC Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, FLGC has a market cap of 12M. Regarding current trading prices, ORGO is priced at $4.89, while FLGC trades at $21.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas FLGC's P/E ratio is -0.60. In terms of profitability, ORGO's ROE is -0.03%, compared to FLGC's ROE of -2.98%. Regarding short-term risk, ORGO is more volatile compared to FLGC. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check FLGC's competition here
ORGO vs AGRX Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ORGO is priced at $4.89, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ORGO's ROE is -0.03%, compared to AGRX's ROE of +0.66%. Regarding short-term risk, ORGO is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check AGRX's competition here
ORGO vs BFRI Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, BFRI has a market cap of 10.1M. Regarding current trading prices, ORGO is priced at $4.89, while BFRI trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas BFRI's P/E ratio is -0.52. In terms of profitability, ORGO's ROE is -0.03%, compared to BFRI's ROE of -11.51%. Regarding short-term risk, ORGO is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for ORGO.Check BFRI's competition here
ORGO vs TLPH Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, TLPH has a market cap of 10.1M. Regarding current trading prices, ORGO is priced at $4.89, while TLPH trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas TLPH's P/E ratio is -1.26. In terms of profitability, ORGO's ROE is -0.03%, compared to TLPH's ROE of -1.51%. Regarding short-term risk, ORGO is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for ORGO.Check TLPH's competition here
ORGO vs EVOK Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, EVOK has a market cap of 8.6M. Regarding current trading prices, ORGO is priced at $4.89, while EVOK trades at $5.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas EVOK's P/E ratio is -4.42. In terms of profitability, ORGO's ROE is -0.03%, compared to EVOK's ROE of -0.99%. Regarding short-term risk, ORGO is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check EVOK's competition here
ORGO vs SNOA Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, SNOA has a market cap of 8.4M. Regarding current trading prices, ORGO is priced at $4.89, while SNOA trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas SNOA's P/E ratio is -2.30. In terms of profitability, ORGO's ROE is -0.03%, compared to SNOA's ROE of -0.76%. Regarding short-term risk, ORGO is more volatile compared to SNOA. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check SNOA's competition here
ORGO vs NLTX Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ORGO is priced at $4.89, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ORGO's ROE is -0.03%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ORGO is more volatile compared to NLTX. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check NLTX's competition here
ORGO vs BFRIW Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, BFRIW has a market cap of 7.6M. Regarding current trading prices, ORGO is priced at $4.89, while BFRIW trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas BFRIW's P/E ratio is -0.07. In terms of profitability, ORGO's ROE is -0.03%, compared to BFRIW's ROE of -11.51%. Regarding short-term risk, ORGO is less volatile compared to BFRIW. This indicates potentially lower risk in terms of short-term price fluctuations for ORGO.Check BFRIW's competition here
ORGO vs LCI Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ORGO is priced at $4.89, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas LCI's P/E ratio is -0.04. In terms of profitability, ORGO's ROE is -0.03%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ORGO is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for ORGO.Check LCI's competition here
ORGO vs BGXX Comparison August 2025
ORGO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 620.3M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, ORGO is priced at $4.89, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of -34.93, whereas BGXX's P/E ratio is -0.76. In terms of profitability, ORGO's ROE is -0.03%, compared to BGXX's ROE of -0.35%. Regarding short-term risk, ORGO is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for ORGO.Check BGXX's competition here